Please wait while the formulary information is being retrieved.
MYLOTARG (GEMTUZUMAB OZOGAMICIN)
- Cd33 positive acute myeloid leukemia
4.5 mg (1 mg/mL initial concentration) intravenous solution
- Dosage information is not available
Cd33 positive acute myeloid leukemia
- Infuse 6 mg/m2 over 2 hour(s) by intravenous route on day 1 of induction cycle
- Infuse 3 mg/m2 over 2 hour(s) by intravenous route on day 8 of induction cycle
- Infuse 2 mg/m2 over 2 hour(s) by intravenous route once every 28 daysfor up to 8 cycles
- Infuse 3 mg/m2 over 2 hour(s) by intravenous route on days 1, 4 and 7Of induction cycle
- Infuse 3 mg/m2 over 2 hour(s) by intravenous route on day 1 of consolidation cycle for 2 cycles
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Hepatic veno-occlusive disease
- Lactating mother
Contraindicated
- Bone marrow depression
- Disease of liver
- Pregnancy
Severe
Moderate
- None
MYLOTARG (GEMTUZUMAB OZOGAMICIN)
- Cd33 positive acute myeloid leukemia
- Abnormal hepatic function tests
- Anemia
- Chills
- Fever
- Headache disorder
- Hyperbilirubinemia
- Hypokalemia
- Hypotension
- Hypoxia
- Infection
- Nausea
- Neutropenic disorder
- Pneumonia
- Stomatitis
- Tachycardia
- Thrombocytopenic disorder
- Vomiting
- Constipation
- Fatigue
- Skin rash
More Frequent
Severe
Less Severe
- Dyspnea
- Hepatic veno-occlusive disease
- Intracranial bleeding
- Kidney disease with reduction in GFR
- Pulmonary edema
- Diarrhea
- Pain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory distress syndrome
- Acute respiratory insufficiency
- Anaphylaxis
- Bacterial sepsis
- Fungal infection of lung
- Hemorrhage
- Hemorrhagic cystitis
- Hypersensitivity drug reaction
- Interstitial pneumonitis
- Intracranial hematoma
- Neutropenic colitis
- Subdural intracranial hemorrhage
Less Severe
- Hepatitis
Contraindicated
None
Severe Precaution
Gemtuzumab
Not indicated for pediatrics. No safety studies performed
- 1 Day – 18 Years
- Not indicated for pediatrics. No safety studies performed
Management or Monitoring Precaution
None
Gemtuzumab
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Gemtuzumab
Potential for serious adverse effects on nursing infant
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Potential for serious adverse effects on nursing infant |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Gemtuzumab
General-In clinical trials, elderly patients experienced a higher rate of fever and severe or greater infections compared to younger patients.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may cause very serious (even fatal) liver damage, including a certain type known as veno-occlusive disease (VOD). The risk is increased with higher doses, or if you already have liver problems, or if you have had a bone marrow transplant. Careful monitoring by your doctor may decrease your risk.<br /><br />Tell your doctor right away if you develop nausea/vomiting that doesn't stop, loss of appetite, stomach/abdominal pain, yellowing eyes/skin, dark urine, swelling abdomen, sudden weight gain. Your doctor may change your dosage schedule or stop treatment with this medication if you develop VOD.
| Cd33 positive acute myeloid leukemia | |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| 0-9 | A-Z |
|---|---|
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
Formulary Reference Tool